Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.
about
Immunolocalization of cyclotides in plant cells, tissues and organ supports their role in host defense.Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.New Modalities for Challenging Targets in Drug Discovery.Novel approaches to the design of bioavailable melanotropins.Discovery, structure, function, and applications of cyclotides: circular proteins from plants.Discovery and optimization of peptide macrocycles.In vitro-engineered non-antibody protein therapeutics.Cyclotides: Overview and Biotechnological Applications.Cyclotides Isolated from an Ipecac Root Extract Antagonize the Corticotropin Releasing Factor Type 1 Receptor.Chemical Proteomics for Target Discovery of Head-to-Tail Cyclized Mini-Proteins.Cyclotides, a versatile ultrastable micro-protein scaffold for biotechnological applications.Co-expression of a cyclizing asparaginyl endopeptidase enables efficient production of cyclic peptides in planta.Intramolecular Thioether Crosslinking to Increase the Proteolytic Stability of Affibody Molecules.Precisely Regulated and Efficient Locking of Linear Peptides into Stable Multicyclic Topologies through a One-Pot Reaction.The N-terminal pro-domain of the kalata B1 cyclotide precursor is intrinsically unstructured.Decarboxylative Peptide Macrocyclization through Photoredox Catalysis.Inhibition of Breast Cancer Cell Migration by Cyclotides Isolated from Pombalia calceolaria.Discovery of peptide probes to modulate oxytocin-type receptors of insectsPeptides as Therapeutic Agents for Inflammatory-Related Diseases
P2860
Q36072123-3153EA39-4191-4621-A0C6-DEEA324D37AEQ36290143-DD1AE342-43B3-49EE-A735-5436D810F149Q38289100-A69B8473-76DA-4FFE-8D3C-478505206293Q38658728-8FA364D3-3637-46F5-811D-507BB882E934Q38843873-26758E32-077F-4167-9F1F-BE2B6DE44DC7Q38975684-B5ACDA1D-7B46-4595-A050-36CD0F4AF2F3Q39167522-D5E0FB73-2150-4CD9-900B-3FE3CEA39382Q39330201-9DA69238-4C4B-4102-A982-7DB989CC023EQ42369922-9B68C2A6-75AA-4326-8F53-10413A53A714Q42654389-84B15737-106A-4AB7-9053-7713FEA1BECCQ46003077-77EB3494-E57D-49D8-888C-91167F6E19A0Q47224864-C8DD5528-B181-4A4A-B2C0-A476034D8D3AQ47760140-8BF88D92-3483-46E5-B159-7E726A113DFCQ48820981-57D59F54-344F-4325-A3A4-53C46932123AQ51548789-EB5535E2-DBEC-452D-B010-EB29ED9207FFQ54335053-F4E9C918-7D34-4B69-8377-6A4DCB1067E3Q55004815-D2185BB9-3781-4EE7-8BE0-CCF14065F800Q57128056-9CF4ACB3-66F2-4801-942D-45A749F83763Q58749714-022B1FAA-99C6-42B4-9A1F-B107AE914D84
P2860
Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.
@en
type
label
Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.
@en
prefLabel
Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.
@en
P2093
P2860
P50
P356
P1476
Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis.
@en
P2093
Carsten Gründemann
Emine Sahin
Gernot Schabbauer
Kathrin Thell
Markus Gold-Binder
Paul Michenthaler
Zita Liutkevičiūtė
P2860
P304
P356
10.1073/PNAS.1519960113
P407
P577
2016-03-28T00:00:00Z